...
首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Revascularization of lower extremity chronic total occlusions with a novel intraluminal recanalization device: Results of the ReOpen study
【24h】

Revascularization of lower extremity chronic total occlusions with a novel intraluminal recanalization device: Results of the ReOpen study

机译:用新型腔内再通装置对下肢慢性总闭塞进行血运重建:ReOpen研究的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To report outcomes of a multicenter, nonrandomized study evaluating the safety and effectiveness of a guidewire-mounted mechanical recanalization device with a rotating distal tip (TruePath) in facilitating the crossing of infrainguinal chronic total occlusions (CTOs). Methods: Eligible patients had lower extremity ischemia and an angiographically confirmed occlusion, with no antegrade flow for at least 30 days, in an infrainguinal artery. Enrollment occurred when a previous or concurrent attempt to cross the CTO with a conventional guidewire had failed. A total of 85 patients with 85 lesions were enrolled; 61 (71.8%) target lesions were in the superficial femoral artery and 68 (80%) were considered moderately or heavily calcified. Clinical evaluations were assessed immediately post procedure and at 30- day follow-up. Results: Freedom from clinical perforation at the time of the procedure was achieved in 98.8% of patients. The device facilitated CTO crossing into the distal true lumen (technical success) in 68 (80.0% ) patients, with subsequent distal guidewire positioning in 65 (76.5%). The average ABI (n=58) improved from 0.65 (range 0.35-1.20) at baseline to 1.00 (range 0.50-2.00) through 30-day follow-up. Symptoms improved in 70 (82.4%) patients upon treatment, and improvement was maintained in 57/70 (81.4%) through 30 days. Conclusion: The ReOpen Study demonstrated that the TruePath device is safe and effective for facilitating crossing of CTOs resistant to conventional guidewire maneuvers.
机译:目的:报告一项多中心,非随机研究的结果,该研究评估带有旋转远侧末端(TruePath)的引导线安装的机械再通装置在促进跨导管下慢性总闭塞(CTO)的安全性和有效性。方法:符合条件的患者具有下肢缺血且经血管造影证实为闭塞,并且在下鞘动脉中至少30天没有顺行血流。当先前或同时尝试通过常规导丝穿越CTO失败时,就会发生注册。总共招募了85名患者,其中有85个病灶。 61例(71.8%)目标病变位于股浅动脉,其中68例(80%)被认为是中度或重度钙化。手术后和术后30天立即评估临床评估。结果:98.8%的患者在手术时无临床穿孔。该设备有助于68例(80.0%)患者的CTO跨入远端真管腔(技术成功),随后在65例(76.5%)中进行远端导丝定位。通过30天的随访,平均ABI(n = 58)从基线的0.65(范围0.35-1.20)提高到1.00(范围0.50-2.00)。治疗后70例患者(82.4%)的症状得到改善,并且在30天内症状改善率保持在57/70例(81.4%)。结论:ReOpen研究表明,TruePath装置对于促进穿越常规导线操作的CTO而言是安全有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号